Health

Antidepressants and mental health medications

SSRIs, SNRIs, mood stabilizers, and ADHD medications with high API import reliance from India and China.

Why it matters · Refill delays and forced therapeutic substitutions for millions of Americans managing chronic mental health conditions.

Inputs

Companies

Facilities

Source countries

How it's made

The process

01
Key Starting Material (KSM) Synthesis
Chemical synthesis of KSMs and intermediates, including fluorination steps for SSRIs; produced primarily in China, these precursors are the true upstream chokepoint for psychiatric drugs
02
API Synthesis
Multi-step organic synthesis converting KSMs into finished APIs (sertraline, fluoxetine, clozapine, alprazolam, etc.); dominated by Indian and Chinese contract manufacturers
03
API Purification & Release Testing
Crystallization, recrystallization, and chromatographic purification; API tested for identity, purity, and potency per FDA/ICH specifications before release
04
Granulation & Blending
API combined with excipients (binders, fillers, disintegrants); wet or dry granulation creates uniform flowable granules for compression
05
Tablet Compression & Coating
Granules compressed into tablets; film or enteric coating applied for moisture and light protection, taste masking, or controlled release
06
Quality Control & Batch Release
Assay, dissolution, content uniformity, and stability testing; FDA-required batch records reviewed; batches approved or rejected before distribution
07
Blister Packaging & Distribution
Tablets sealed in aluminum blister packs or bottles; secondary packaging with labeling; temperature-controlled distribution for stability-sensitive formulations

What it's made of

The inputs

3 raw inputs feed antidepressants and mental health medications. Inputs flagged with ● are critical, without them, production halts.

pharmaceutical

●

Psychiatric Drug Active Pharmaceutical Ingredients

Dependency 98%

chemical

●

Pharmaceutical Key Starting Materials (KSMs)

Dependency 95%

chemical

Pharmaceutical Excipients (Oral Solid Dose)

Dependency 60%

Where it comes from

Country dependencies

Weighted share of upstream inputs sourced from each country.

Country	Weighted share	Inputs supplied to antidepressants and mental health medications
CNChina	42%	Pharmaceutical Key Starting Materials (KSMs) · Psychiatric Drug Active Pharmaceutical Ingredients
INIndia	38%	Pharmaceutical Key Starting Materials (KSMs) · Psychiatric Drug Active Pharmaceutical Ingredients
ILIsrael	10%	Psychiatric Drug Active Pharmaceutical Ingredients
DEGermany	5%	Pharmaceutical Key Starting Materials (KSMs) · Psychiatric Drug Active Pharmaceutical Ingredients
USUnited States	4%	Pharmaceutical Key Starting Materials (KSMs)

Who makes it

Supplier companies

10 companies in this supply chain, sorted by market share.

Juhua Group Corporation →(600636.SS)

HQ CN15% share

China's largest fluorochemical producer; manufactures fluorination intermediates used as KSMs for SSRIs (sertraline, fluoxetine, escitalopram) and other fluorine-containing pharmaceuticals

Supplies these inputs

Pharmaceutical Key Starting Materials (KSMs)

Replaceability

Substitutability 20% · 18 mo to replace

Business segments

Fluoropolymers (PTFE, PVDF, FEP)30% rev
Pharmaceutical Key Starting Materials (KSMs)25% rev
Refrigerants (HFCs)25% rev
Fluorocarbon Solvents + Electronic Chemicals20% rev

Divi's Laboratories Limited →

HQ IN12% share

Indian pharmaceutical API manufacturer (NSE: DIVISLAB, HQ Hyderabad; ~₹75B revenue); one of India's largest and most technically sophisticated pharmaceutical API producers, specializing in complex APIs including fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin), carotenoids (nutraceuticals), and custom synthesis for branded pharmaceutical companies. Divi's Laboratories has never been involved in a major USFDA warning letter or import alert (unusual for an Indian API company of its scale) — maintaining essentially clean regulatory compliance across its multiple Visakhapatnam, Andhra Pradesh production facilities. Divi's produces fluoroquinolone APIs including ciprofloxacin HCl for ophthalmic applications for global generic pharmaceutical customers. Divi's is also one of India's most consistently profitable pharmaceutical companies — its focus on volume API production at high quality has created a near-uninterruptible supply chain position across multiple essential medicines.

Supplies these inputs

Pharmaceutical Key Starting Materials (KSMs)

Replaceability

Substitutability 55% · 12 mo to replace

Business segments

Generic APIs55% rev
Custom Synthesis (Pharma CDMO)30% rev
Nutraceuticals (Carotenoids)15% rev

Teva API (TAPI) →(TEVA)

HQ IL12% share

World's largest supplier of azithromycin API for regulated markets. TAPI is Teva's dedicated API business supplying both Teva's own generics and third-party manufacturers.

Supplies these inputs

Psychiatric Drug Active Pharmaceutical Ingredients

Replaceability

Substitutability 50% · 12 mo to replace

Business segments

Azithromycin API (World #1)30% rev
Psychiatric and Other APIs30% rev
TEVA Parent Context40% rev

CSPC Pharmaceutical Group Limited →

HQ CN10% share

Chinese pharmaceutical company (HKEX: 1093, HQ Shijiazhuang Hebei; ~HKD 30B revenue); one of China's largest cephalosporin API and finished dose pharmaceutical manufacturers. CSPC produces 7-ACA, cephalosporin APIs (cephalexin, ceftriaxone, cefazolin), and downstream finished dose cephalosporin antibiotics for domestic and export markets. CSPC's Zhongrun Division is one of China's largest cephalosporin API producers. CSPC is headquartered in Shijiazhuang, Hebei — the same city as NCPC (North China Pharmaceutical), making Shijiazhuang the world's most concentrated antibiotic API manufacturing city. Hebei Province collectively produces a dominant fraction of global penicillin, cephalosporin, and other antibiotic APIs.

Supplies these inputs

Pharmaceutical Key Starting Materials (KSMs)

Replaceability

Substitutability 30% · 18 mo to replace

Business segments

Cephalosporin APIs (Zhongrun Division)30% rev
Innovative Drugs (Patented/Branded)35% rev
Common Drugs (Generic Finished Dose)25% rev
Consumer Healthcare10% rev

Sun Pharmaceutical Industries →(SUNPHARMA.NS)

HQ IN10% share

World's fourth-largest specialty generic pharma company and India's largest by market cap; major global supplier of psychiatric generics including antidepressants and antipsychotics

Supplies these inputs

Psychiatric Drug Active Pharmaceutical Ingredients

Replaceability

Substitutability 40% · 12 mo to replace

Business segments

US Generics (Largest Segment)33% rev
India Formulations (Domestic Branded)27% rev
Specialty Branded (Taro + Innovation)20% rev
Rest of World + Emerging Markets15% rev

Aurobindo Pharma →(AUROPHARMA.NS)

HQ IN8% share

India's second-largest pharma company by revenue; major manufacturer of SSRIs, antipsychotic APIs, and finished formulations for the US and EU markets

Supplies these inputs

Psychiatric Drug Active Pharmaceutical Ingredients

Replaceability

Substitutability 35% · 12 mo to replace

Business segments

Antibiotics (Semi-Synthetic Penicillins + Cephalosporins)30% rev
CNS / SSRIs + Antipsychotics (US Market)25% rev
Antiretrovirals (Global HIV Programs)20% rev
Injectable + Oncology15% rev

Zhejiang Medicine Co., Ltd. →

HQ CN8% share

Zhejiang Medicine Co., Ltd. (Shaoxing, Zhejiang China; SZSE: 000989) is China's largest Vitamin E manufacturer (world's #2) and a major producer of steroid hormone KSMs used in pharmaceutical synthesis. Zhejiang Medicine's steroid intermediate products (including diosgenin-derived pregnenolone, progesterone, and dehydroepiandrosterone) are upstream KSMs for corticosteroids (prednisone, dexamethasone, triamcinolone) — the anti-inflammatory drugs used across rheumatoid arthritis, asthma, COVID-19 treatment, transplant rejection, and oncology. Zhejiang Medicine also produces Vitamin A, Vitamin D3, and carotenoids — key nutritional KSMs for pharmaceutical and food supplement applications. The company represents the dual nature of Chinese pharmaceutical precursor dominance: food supplement vitamins and pharmaceutical steroids made in the same Zhejiang province chemical industrial base.

Supplies these inputs

Pharmaceutical Key Starting Materials (KSMs)

Replaceability

Substitutability 35% · 18 mo to replace

Business segments

Vitamin E (Tocopherols)40% rev
Steroid Hormone Intermediates & KSMs30% rev
Vitamins A, D & Carotenoids20% rev
Other Pharmaceutical Products10% rev

Viatris Inc →(VTRS)

HQ US7% share

US generic pharmaceutical company (spun off from Pfizer/Mylan 2020); first FDA approval for generic Restasis (cyclosporine ophthalmic emulsion) February 2022.

Supplies these inputs

Psychiatric Drug Active Pharmaceutical Ingredients

Replaceability

Substitutability 50% · 12 mo to replace

Business segments

Developed Markets (Generic + Branded Generics)50% rev
Emerging Markets30% rev
Janz (Biosimilars)20% rev

Dr. Reddy's Laboratories →

HQ IN6% share

Indian multinational pharmaceutical company (NSE: DRREDDY; HQ Hyderabad) with significant irinotecan API and finished dose manufacturing. Dr. Reddy's manufactures irinotecan hydrochloride injection for the U.S. and European generic markets — one of the leading generic irinotecan suppliers approved by FDA and EMA. The company converts camptothecin (procured primarily from Chinese botanical extraction sources) into irinotecan API via semi-synthesis at its Hyderabad API facilities. Dr. Reddy's broader oncology generics franchise includes paclitaxel, docetaxel, and topotecan, making it one of the few Indian companies with a full camptothecin-class API portfolio. Supply of irinotecan to the U.S. critical care oncology market is a significant part of the company's FDA-regulated generic pharmaceutical business.

Supplies these inputs

Pharmaceutical Key Starting Materials (KSMs)

Replaceability

Substitutability 55% · 12 mo to replace

Business segments

Global Generics (Finished Dose)60% rev
Pharmaceutical Services & Active Ingredients (PSAI)25% rev
Proprietary Products & Nutraceuticals10% rev
Other Businesses5% rev

Zhejiang Huahai Pharmaceutical →(002401.SZ)

HQ CN5% share

Major Chinese API manufacturer supplying psychiatric and cardiovascular APIs globally; received FDA warning letter in 2018 after NDMA contamination in its valsartan API

Supplies these inputs

Psychiatric Drug Active Pharmaceutical Ingredients

Replaceability

Substitutability 30% · 12 mo to replace

Business segments

Cardiovascular APIs (ARBs — Angiotensin Receptor Blockers)45% rev
CNS / Psychiatric APIs30% rev
Formulations (Finished Dosage)15% rev
R&D + Other APIs10% rev

Where it's made

Facilities

4 facilities producing inputs that feed antidepressants and mental health medications.

Aurobindo Unit III – API Manufacturing →

Aurobindo Pharma · Hyderabad, Telangana · API Manufacturing

FDA-approved API facility; manufactures SSRIs and other psychiatric APIs for US market

Huahai Cangnan API Plant →

Zhejiang Huahai Pharmaceutical · Cangnan, Zhejiang · API Manufacturing

Primary API manufacturing site; received FDA warning letter in 2018 after NDMA contamination in valsartan API; also supplies psychiatric APIs

Juhua Quzhou Fluorochemical Base →

Juhua Group Corporation · Quzhou, Zhejiang · Chemical Manufacturing

China's largest fluorochemical production base; manufactures KSMs and fluorination intermediates used upstream of SSRI API synthesis

Sun Pharma Halol Plant →

Sun Pharmaceutical Industries · Halol, Gujarat · Formulations

Major US-facing formulations plant; received FDA import alert in 2014 (resolved 2017); key psychiatric formulations facility

← Browse all goods